

IMMUNE CHECKPOINT INHIBITORS: ARE WE READY FOR COMBINATION?

**HALL B3 -
ROOM 22**
MESSE MUNICH
MUNICH, GERMANY

Chair

John Haanen
Amsterdam, Netherlands

SUNDAY, 21 OCTOBER 2018
13:00-14:30

-
- | | |
|-------|---|
| 13:00 | Introduction
<i>John Haanen, Amsterdam, Netherlands</i> |
| 13:05 | Mechanisms of chemotherapy-induced increased immune response
<i>Johan Vansteenkiste, Leuven, Belgium</i> |
| 13:15 | Achievements and present development in lung cancer
<i>Marina Garassino, Milan, Italy</i> |
| 13:40 | Where do we stand in triple negative breast cancer (TNBC)?
<i>Sherene Loi, Melbourne, Australia</i> |
| 14:05 | Which patients do benefit? How to select and for which benefit?
<i>John Haanen, Amsterdam, Netherlands</i> |
| 14:25 | Conclusion
<i>John Haanen, Amsterdam, Netherlands</i> |

This educational activity is provided
by ESMO and supported by Celgene.

